TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Vaccinex (VCNX).
Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pepinemab antibody for treating Alzheimer’s disease. This update, which could potentially impact the company’s stock, is not intended for regulatory filing purposes but offers a glimpse into ongoing research and development efforts that could be significant for investors and stakeholders tracking advancements in Alzheimer’s treatments.
For detailed information about VCNX stock, go to TipRanks’ Stock Analysis page.